Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients … – GlobeNewswire (press release)
|
Novartis CAR–T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients …
GlobeNewswire (press release) Basel, April 18, 2017 – Novartis announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adult … |
